Announcements Trials
Browse Landscape

Phase

Phase 2 27Phase 3 15Phase 1/2 5Phase EARLY_PHASE1 2Phase 4 2Phase 1 2Phase NA 1

Status

Completed 3Terminated 2Recruiting 2Unknown 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 1Breast 1

Conditions

Renal Insufficiency 1Multiple Myeloma 1Breast Neoplasms 1

Interventions

Magnetic Resonance Spectroscopy 17Cyclophosphamide 16fludarabine 12Specimen Handling 12Fluorodeoxyglucose F18 7pembrolizumab 6X-Rays 6Nivolumab 6Temozolomide 5Radiotherapy 5Immunotherapy, Adoptive 5lenvatinib 4Paclitaxel 4Leukapheresis 4Immune Checkpoint Inhibitors 4Etoposide 4Cisplatin 4Carboplatin 4ruxolitinib 3fluciclovine F-18 3Tirzepatide 3Surgical Procedures, Operative 3Doxorubicin 3Dasatinib 3Cholecalciferol 3Biopsy 368Ga-FAPI 32-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 3tislelizumab 2palbociclib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Recruiting × Bortezomib × Clear all
NCT06142396 2026-03-12

Pilot Study Dara-CyBorD in Newly Diagnosed Multiple Myeloma Patients With Renal Failure

Augusta University

Phase EARLY_PHASE1 Recruiting
30 enrolled
Plasma cell

Multiple Myeloma, Renal Insufficiency

NCT04265872 2026-02-12

Bortezomib Followed by Pembrolizumab and Cisplatin in metTNBC

Baylor Research Institute

Phase EARLY_PHASE1 Recruiting
20 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡